SCHEMBL14320666

SCHEMBL14320666

COc1cccc(-c2nc(Nc3ccc(N(C)C)cc3)c3[nH]ncc3n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 9/20 0.53
SYK P43405 3/20 0.51
ABCG2 Q9UNQ0 6/20 0.50
ABCB1 P08183 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
CASP1 P29466 1/20 0.50
CYP2C19 P33261 1/20 0.50
CASP7 P55210 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
JAK2 O60674 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14321144 0.88 KDM1A (0.65) KDM1ASYKABCG2MEN1KMT2A
SCHEMBL14321184 0.86 KDM1A (0.54) KDM1AABCG2ABCB1TP53MAPT
SCHEMBL14320756 0.86 ABCG2 (0.67) SYKABCG2ABCB1MEN1KMT2A
SCHEMBL14320367 0.85 KDM1A (0.66) KDM1ASYKMEN1KMT2AKDM4E
SCHEMBL14320390 0.84 ABCG2 (0.53) SYKABCG2ABCB1MEN1KMT2A
SCHEMBL14320630 0.83 ABCG2 (0.59) ABCG2ABCB1MEN1KMT2AKDM4E
SCHEMBL14320896 0.82 ABCG2 (0.68) ABCG2ABCB1MEN1KMT2AKDM4E
SCHEMBL14320593 0.81 SYK (0.59) SYKABCG2ABCB1MEN1KMT2A
SCHEMBL14320671 0.81 JAK2 (0.57) KDM1ASYKKDM4ECYP1A2CYP3A4
SCHEMBL14320592 0.81 SYK (0.69) SYKABCG2ABCB1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK KDM1A 1770/4885SYK 11/4885ABCG2 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.